1. A compound represented by the formula:
Wherein
X is O or S;
Y is O, S or NR3;
Z is C(R2)2c;
the ring system indicated by figure II represents a 5 or 6 membered aryl group
and is selected from the group consisting of
the ring system indicated by figure III represents a 5 or 6 membered aryl group
and is selected from the group consisting of
R1 is selected from the group consisting of halogen, aryl, C1 to C8 alkyl, CF3, OCF3, OCF2H, S(O)fR2, (CR3R4)dC(O)OR2, O(CR3R4)eC(O)OR2, NR2(CR3R4)dC(O)R2, NR2(CR3R4)dC(O)OR2, OP(O)(OR2)2, OC(O)OR2, OCH2O, NR2(CH2)eN(R2)2, O(CH2)eN(R2)2, (CR3R4)dCN, O(CR3R4)eCN, (CR3R4)dAr, NR2(CR3R4)dAr, O(CR3R4)dAr, S(O)f(CR3R4)dAr, (CR3R4)dSO2R2, (CR3R4)dC(O)N(R2)2, NR2(CR3R4)dC(O)N(R2)2, O(CR3R4)dC(O)N(R2)2, S(O)f(CR3R4)eC(O)N(R2)2, CR3R4)dOR2, NR2(CR3R4)eOR2, O(CR3R4)eOR2, S(O)f(CR3R4)dOR2, C(O)(CR3R4)dR3, NR2C(O)(CR3R4)dR3, OC(O)(CR3R4)dN(R2)2, C(O)(CR3R4)dN(R2)2, NR2C(O)(CR3R4)dN(R2)2, OC(O)(CR3R4)dN(R2)2, (CR3R4)dR3, NR2(CR3R4)dR3, O(CR3R4)dR3, S(O)f(CR3R4)dR3, (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2, S(O)f(CR3R4)dN(R2)2, N(R5)2, OR5, C(O)R5, S(O)fR5, C(O)ArNR2C(O)Ar, NR2ArNR2C(O)Ar, OArNR2C(O)Ar, SArNR2C(O)Ar, C(O)ArC(O)(NR2)2, OArC(O)(NR2)2, NR2ArC(O)(NR2)2, SArC(O)(NR2)2C(O)ArC(O)NR2Ar, OArC(O)NR2Ar, NR2ArC(O)NR2Ar and SArC(O)NR2Ar;
R2 is selected from the group consisting of hydrogen, C1 to C8 alkyl, C1 to C8 alkenyl, C1 to C8 alkynyl, C1 to C4 alkylol, lower alkylphenyl, phenyl, (CR3R4)dAr, OC(O)R7, (CR3R4)dC(O)OR7, (CR3R4)dSO2R7, (CR3R4)dSO2N(R7)2(CR3R4)dOR7, (CR3R4)dOSO2R7, (CR3R4)dP(O)(OR7)2, (CR3R4)dR7, (CR3R4)eN(R7)2 and (CR3R4)eNR7C(O)N(R7)2 wherein N(R2)2 and N(R7)2 may form a 3-7 membered heterocyclic ring and C(R2)2c may form a 3-7 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring may be substituted with one or more of R3;
R is selected from the group consisting of halogen, C1 to C8 alkyl, CF3, OCF3, OCF2H, (CR3R4)dCN, NR2(CR3R4)eCN, O(CR3R4)eCN, S(O)fR2, (CR3R4)dC(O)OR2, (CR3R4)dC(O)R2, (CR3R4)dC(OR2)2, NR2(CR3R4)dC(O)OR2, O(CR3R4)dC(O)OR2, S(O)f(CR3R4)dC(O)OR2, (CR3R4)dAr, NR2(CR3R4)dAr, O(CR3R4)dAr, S(O)f(CR3R4)dAr, (CR3R4)dSO2R2, NR2(CR3R4)dS(O)fR2, O(CR3R4)dS(O)fR2, S(O)f(CR3R4)eS(O)fR2, (CR3R4)dC(O)N(R2)2, NR2(CR3R4)dC(O)N(R2)2, O(CR3R4)dC(O)N(R2)2, S(O)f(CR3R4)eC(O)N(R2)2, (CR3R4)dOR2, NR2(CR3R4)eOR2, O(CR3R4)eOR2, S(O)f(CR3R4)dOR2, (CR3R4)dOSO2R2, NR2(CR3R4)eOSO2R2, O(CR3R4)eOSO2R2, S(O)f(CR3R4)eOSO2R2(CR3R4)dP(O)(OR2)2, NR2(CR3R4)dP(O)(OR2)2, O(CR3R4)dP(O)(OR2)2 , S(O)f(CR3R4)eP(O)(OR2)2, C(O)(CR3R4)dR3, NR2C(O)(CR3R4)dR3, OC(O)(CR3R4)dN(R2)2, C(O)(CR3R4)dN(R2)2, C(O)NR2(CR3R4)eN(R2)2, NR2C(O)(CR3R4)dN(R2)2, OC(O)(CR3R4)dN(R2)2, (CR3R4)dR3, NR2(CR3R4)dR3, O(CR3R4)dR3, S(O)f(CR3R4)dR3, HNC(O)R2, HN\u2014C(O)OR2, (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2, S(O)f(CR3R4)dN(R2)2, OP(O)(OR2)2, OC(O)OR2, OCH2O, HN\u2014CH\u2550CH, \u2014N(COR2)CH2CH2, HC\u2550N\u2014NH, N\u2550CH\u2014S, (CR3R4)dC\u2550C(CR3R4)dR2, (CR3R4)dC\u2550C(CR3R4)dOR2, (CR3R4)dC\u2550C(CR3R4)dN(R2)2, (CR3R4)dCC(CR3R4)dR2,
(CR3R4)dCC(CR3R4)eOR2, (CR3R4)dCC(CR3R4)eN(R2)2, (CR3R4)dC(O)(CR3R4)dR2, (CR3R4)dC(O)(CR3R4)dOR2 and (CR3R4)dC(O)(CR3R4)dN(R2)2 and (CR3R4)dR5;
R3 and R4 may be selected from the group consisting of H, F, hydroxy, C1-C4 alkyl, (CR8R9)dOR8, (CR8R9)dO(CR8R9)eOR8, (CR8R9)dCOOR8 and (CR8R9)dN(R8)2 or CR3R4 may represent a carbocyclic or heterocyclic ring of from 3 to 6 carbons or, alternatively, (CR3R4)d and (CR3R4)e may form a 3-7 membered carbocyclic or heterocyclic ring;
R5 is an aryl group or a substituted oxindole;
R6 is selected from the group consisting of hydrogen, C1-C8 alkyl, hydroxymethyl and phenyl;
R7 is selected from the group consisting of hydrogen, hydroxyl, F, C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C1 to C4 alkylol, lower alkylphenyl and phenyl;
R8 and R9 are selected from the group consisting of hydrogen, hydroxyl, F, C2 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C1 to C4 alkylol, lower alkylphenyl and phenyl;
a is 0 or an integer of from 1 to 3;
b is 0 or an integer of from 1 to 2;
c is an integer of from 1 to 2;
d is 0 or an integer of from 1 to 5;
e is an integer of from 1 to 4;
f is 0 or an integer of from 1 to 2, and further provided any of said alkyl or aryl radicals may be substituted with one or two halo, hydroxy, lower alkyloxy or lower alkyl amino radicals, including cycloalkylamino radicals and wherein the alkyl, or the cycloalkyl amino ring, can include an enchained oxygen, sulfur or additional nitrogen atom and may be substituted with one or two halo or lower alkyl radicals;
and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein Y is O.
3. The compound of claim 1 wherein X is O.
4. The compound of claim 1 wherein X is O and Y is O.
5. The compound of claim 1 wherein b is 0 or b is 1 and R1 is F.
6. The compound of claim 4 wherein R6 is H.
7. The compound of claim 6 wherein
is selected from the group consisting of phenyl and pyridyl.
8. The compound of claim 7 wherein
is selected from the group consisting of
9. The compound of claim 5 wherein
is selected from the group consisting of pyridyl, thienyl and furanyl.
10. The compound of claim 8 wherein
is selected from the group consisting of
11. The compound of claim 5 wherein c is 1.
12. The compound of claim 11 wherein one of R2 is hydrogen and the other R2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl and phenyl, CH2COOH, CH2SO2CH3, CH2SO2N(R2)2.
13. The compound of claim 5 wherein a is 0 or a is 1 or 2 and is selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkylether and amino lower alkyl groups.
14. The compound of claim 13 wherein R is a amino lower alkyl group and said amino lower alkyl group comprises from 1 to 3 enchained nitrogen atoms and from 0 to 2 enchained oxygen atoms and wherein one or more of the hydrogen atoms in said lower alkyl may be substituted with a hydroxyl, keto or carboxy group.
15. The compound of claim 13 where R is a lower alkyl ether group comprising from 1 to 3 enchained oxygen atoms and wherein one or more of the hydrogen atoms in said lower alkyl may be substituted with a hydroxyl, keto or carboxy group.
16. The compound of claim 14 wherein said amino lower alkyl group is selected from the group consisting of 2-morpholin-4-ylmethyl, 2-(2-morpholin-4-yl-ethyl), 3-(4-hydroxy-piperidin-1-yl)-propyl, 3-Diethylamino-propyl, 2-(3-{4-2-hydroxy-ethoxy)-ethyl-piperazin-1-yl}-propyl, 2-3-(3-hydroxy-piperidin-1-yl)-propyl, 3-2-methoxy-ethyl)-methyl-amino-propyl, 3-(2-methoxy-ethyl)-methyl-amino-propyl, 3-(2,3-Dihydroxy-propyl)-methyl-amino-propyl, 3-(4-methyl-piperazine-1-yl)-propyl and 3-(2Diethylamino-ethyl)-methyl-amino-propyl.
17. The compound of claim 16 wherein said compound is selected from the group consisting of 5-Fluoro-3-(2-morpholin-4-ylmethyl-7H-furo3,4-bpyridin-5-ylidene)-1,3-dihydro-indol-2-one, 5-Fluoro-3-2-(2-morpholin-4-yl-ethyl)-7H-furo3,4-bpyridin-5-ylidene-1,3-dihydro-indol-2-one, 5-Fluoro-3-{2-3-(4-hydroxy-piperidin-1-yl)-propyl-7H-furo3,4-bpyridin-5-ylidene}-1,3-dihydro-indol-2-one, 3-2-(3-Diethylamino-propyl)-7H-furo3,4-bpyridin-5-ylidene-5-fluoro-1,3-dihydro-indol-2-one, 5-Fluoro-3-2-(3-{4-2-(2-hydroxy-ethoxy)-ethyl-piperazin-1-yl}-propyl)-7H-furo3,4-bpyridin-5-ylidene-1,3-dihydro-indol-2-one, 5-Fluoro-3-{2-3-(3-hydroxy-piperidin-1-yl)-propyl-7H-furo3,4-bpyridin-5-ylidene}-1,3-dihydro-indol-2-one, 5-Fluoro-3-(2-{3-(2-methoxy-ethyl)-methyl-amino-propyl}-7H-furo 3,4-bpyridin-5-ylidene)-1,3-dihydro-indol-2-one, 5-Fluoro-3-(2-{3-(2-methoxy-ethyl)-methyl-amino-propyl}-7H-furo3,4-bpyridin-5-ylidene)-1,3-dihydro-indol-2-one, 3-(2-{3-(2,3-Dihydroxy-propyl)-methyl-amino-propyl}-7H-furo3,4-bpyridin-5-ylidene)-5-fluoro-1,3-dihydro-indol-2-one, 5-Fluoro-3-{2-3-(4-methyl-piperazin-1-yl)-propyl-7H-furo3,4-bpyridin-5-ylidene}-1,3-dihydro-indol-2-one and 3-(2-{3-(2-Diethylamino-ethyl)-methyl-amino-propyl}-7H-furo3,4-bpyridin-5-ylidene)-5-fluoro-1,3-dihydro-indol-2-one.
18. The compound of claim 17 wherein said compound is selected from the group consisting of 3-2-(3-Diethylamino-propyl)-7H-furo3,4-bpyridin-5-ylidene-5-fluoro-1,3-dihydro-indol-2-one 5-Fluoro-3-2-(3-{4-2-(2-hydroxy-ethoxy)-ethyl-piperazin-1-yl}-propyl)-7H-furo3,4-bpyridin-5-ylidene-1,3-dihydro-indol-2-one, 5-Fluoro-3-{2-3-(3-hydroxy-piperidin-1-yl)-propyl-7H-furo3,4-bpyridin-5-ylidene}-1,3-dihydro-indol-2-one and 5-Fluoro-3-{2-3-(4-methyl-piperazin-1-yl)-propyl-7H-furo3,4-bpyridin-5-ylidene}-1,3-dihydro-indol-2-one.
19. The compound of claim 4 wherein
c=1;
is phenyl;
is
R is selected from the group consisting of (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2 and C(O)NR2(CR3R4)dN(R2)2; and
a is 1.
20. The compound of claim 4 wherein
c=1;
is phenyl;
is
R is selected from the group consisting of (CR3R4)dN(R2)2, NR2(CR3R4)cN(R2)2, O(CR3R4)eN(R2)2 and C(O)NR2(CR3R4)dN(R2)2; and
a is 1.
21. The compound of claim 4 wherein
c=1;
is phenyl;
is
R is selected from the group consisting of (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2 and C(O)NR2(CR3R4)dN(R2)2; and
a is 1
22. The compound of claim 4 wherein
c=1;
is phenyl;
is
R is selected from the group consisting of (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2 and C(O)NR2(CR3R4)dN(R2)2; and
a is 1
23. The compound of claim 4 wherein
c=1;
is phenyl;
is
R is selected from the group consisting of (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2 and C(O)NR2(CR3R4)dN(R2)2; and
a is 1
24. A method for treating diseases related to unregulated tyrosine kinase signal transduction, which comprises administering to a subject in need thereof, a compound according to claim 1.
25. The method of claim 24 wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
26. The method of claim 25 wherein the blood vessel proliferative disorder is selected from the group consisting of diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, arthritis and restenosis.
27. The method of claim 25 wherein the fibrotic disorder is selected from the group consisting of hepatic cirrhosis, atherosclerosis and surgical adhesions.
28. The method of claim 25 wherein wherein the mesangial cell proliferative disorder is selected from the group consisting of glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies.
29. The method of claim 25 wherein wherein the metabolic disorder is selected from the group consisting of psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases.
30. A compound represented by the formula:
wherein
X is O or S;
Y is O, S or NR3;
Z is C(R2)2c;
the ring system indicated by figure II represents a 5 or 6 membered aryl,
and is selected from the group consisting of
R1 is selected from the group consisting of halogen, aryl, C1 to C8 alkyl, CF3, OCF3, OCF2H, S(O)fR2, (CR3R4)dC(O)OR2, O(CR3R4)eC(O)OR2, NR2(CR3R4)dC(O)R2, NR2(CR3R4)dC(O)OR2, OP(O)(OR2)2, OC(O)OR2, OCH2O, NR2(CH2)eN(R2)2, O(CH2)eN(R2)2, (CR3R4)dCN, O(CR3R4)eCN, (CR3R4)dAr, NR2(CR3R4)dAr, O(CR3R4)dAr, S(O)f(CR3R4)dAr, (CR3R4)dSO2R2, (CR3R4)dC(O)N(R2)2, NR2(CR3R4)dC(O)N(R2)2, O(CR3R4)dC(O)N(R2)2, S(O)f(CR3R4)eC(O)N(R2)2, CR3R4)dOR2, NR2(CR3R4)eOR2, O(CR3R4)eOR2, S(O)f(CR3R4)dOR2, C(O)(CR3R4)dR3, NR2C(O)(CR3R4)dR3, OC(O)(CR3R4)dN(R2)2, C(O)(CR3R4)dN(R2)2, NR2C(O)(CR3R4)dN(R2)2, OC(O)(CR3R4)dN(R2)2, (CR3R4)dR3, NR2(CR3R4)dR3, O(CR3R4)dR3, S(O)f(CR3R4)dR3, (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2, S(O)f(CR3R4)dN(R2)2, N(R5)2, OR5, C(O)R5, S(O)fR5, C(O)ArNR2C(O)Ar, NR2ArNR2C(O)Ar, OArNR2C(O)Ar, SArNR2C(O)Ar, C(O)ArC(O)(NR2)2, OArC(O)(NR2)2, NR2ArC(O)(NR2)2, SArC(O)(NR2)2C(O)ArC(O)NR2Ar, OArC(O)NR2Ar, NR2ArC(O)NR2Ar and SArC(O)NR2Ar;
R2 is selected from the group consisting of hydrogen, C1 to C8 alkyl, C1 to C8 alkenyl, C1 to C8 alkynyl, C1 to C4 alkylol, lower alkylphenyl, phenyl, (CR3R4)dAr, OC(O)R7, (CR3R4)dC(O)OR7, (CR3R4)dSO2R7, (CR3R4)dSO2N(R7)2(CR3R4)dOR4, (CR3R4)dOSO2R7, (CR3R4)dP(O)(OR7)2, (CR3R4)dR7, (CR3R4)eN(R7)2 and (CR3R4)eNR7C(O)N(R7)2 wherein N(R2)2 and N(R7)2 may form a 3-7 membered heterocyclic ring and C(R2)2c may form a 3-7 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring may be substituted with one or more of R3;
R is selected from the group consisting of halogen, C1 to C8 alkyl, CF3, OCF3, OCF2H, (CR3R4)dCN, NR2(CR3R4)eCN, O(CR3R4)eCN, S(O)fR2, (CR3R4)dC(O)OR2, (CR3R4)dC(O)R2, (CR3R4)dC(OR2)2, NR2(CR3R4)dC(O)OR2, O(CR3R4)dC(O)OR2, S(O)f(CR3R4)dC(O)OR2, (CR3R4)dAr, NR2(CR3R4)dAr, O(CR3R4)dAr, S(O)f(CR3R4)dAr, (CR3R4)dSO2R2, NR2(CR3R4)dS(O)fR2, O(CR3R4)dS(O)fR2, S(O)f(CR3R4)eS(O)fR2, (CR3R4)dC(O)N(R2)2, NR2(CR3R4)dC(O)N(R2)2, O(CR3R4)dC(O)N(R2)2, S(O)f(CR3R4)eC(O)N(R2)2, (CR3R4)dOR2, NR2(CR3R4)eOR2, O(CR3R4)eOR2, S(O)f(CR3R4)dOR2, (CR3R4)dOSO2R2, NR2(CR3R4)eOSO2R2, O(CR3R4)eOSO2R2, S(O)f(CR3R4)eOSO2R2(CR3R4)dP(O)(OR2)2, NR2(CR3R4)dP(O)(OR2)2, O(CR3R4)dP(O)(OR2)2, S(O)f(CR3R4)eP(O)(OR2)2, C(O)(CR3R4)dR3, NR2C(O)(CR3R4)dR3, OC(O)(CR3R4)dN(R2)2, C(O)(CR3R4)dN(R2)2, C(O)NR2(CR3R4)eN(R2)2, NR2C(O)(CR3R4)dN(R2)2, OC(O)(CR3R4)dN(R2)2, (CR3R4)dR3, NR2(CR3R4)dR3, O(CR3R4)dR3, S(O)f(CR3R4)dR3, HNC(O)R2, HN\u2014C(O)OR2, (CR3R4)dN(R2)2, NR2(CR3R4)eN(R2)2, O(CR3R4)eN(R2)2, S(O)f(CR3R4)dN(R2)2, OP(O)(OR2)2, OC(O)OR2, OCH2O, HN\u2014CH\u2550CH, \u2014N(COR2)CH2CH2, HC\u2550N\u2014NH, N\u2550CH\u2014S, (CR3R4)dC\u2550C(CR3R4)dR2, (CR3R4)dC\u2550C(CR3R4)dOR2, (CR3R4)dC\u2550C(CR3R4)dN(R2)2, (CR3R4)dCC(CR3R4)dR2,
(CR3R4)dCC(CR3R4)eOR2, (CR3R4)dCC(CR3R4)eN(R2)2, (CR3R4)dC(O)(CR3R4)dR2, (CR3R4)dC(O)(CR3R4)dOR2 and (CR3R4)dC(O)(CR3R4)dN(R2)2 and (CR3R4)dR5;
R3 and R4 may be selected from the group consisting of H, F, hydroxy, C1-C4 alkyl, (CR8R9)dOR8, (CR8R9)dO(CR8R9)eOR8, (CR8R9)dCOOR8 and (CR8R9)dN(R8)2 or CR3R4 may represent a carbocyclic or heterocyclic ring of from 3 to 6 carbons or, alternatively, (CR3R4)d and (CR3R4)e may form a 3-7 membered carbocyclic or heterocyclic ring;
R5 is an aryl group or a substituted oxindole;
R6 is selected from the group consisting of hydrogen, C1-C8 alkyl, hydroxymethyl and phenyl;
R7 is selected from the group consisting of hydrogen, hydroxyl, F, C1 to C9 alkyl, C1 to C8 alkenyl, C1 to C8 alkynyl, C1 to C4 alkylol, lower alkylphenyl and phenyl;
R8 and R9 are selected from the group consisting of hydrogen, hydroxyl, F, C2 to C8 alkyl, C2 to C8 alkenyl, C1 to C8 alkynyl, C1 to C4 alkylol, lower alkylphenyl and phenyl;
a is 0 or an integer of from 1 to 3;
b is 0 or an integer of from 1 to 2;
c is an integer of from 1 to 2;
d is 0 or an integer of from 1 to 5;
e is an integer of from 1 to 4;
f is 0 or an integer of from 1 to 2, and further provided any of said alkyl or aryl radicals may be substituted with one or two halo, hydroxy, lower alkyloxy or lower alkyl amino radicals, including cycloalkylamino radicals and wherein the alkyl, or the cycloalkyl amino ring, can include an enchained oxygen, sulfur or additional nitrogen atom and may be substituted with one or two halo or lower alkyl radicals;
and pharmaceutically acceptable salts thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. Seal arrangement for sealing an application site, comprising:
a sealing element made of a silicone material;
a double-sided adhesive tape for attachment to the sealing element, said tape having a carrier element located between two self-sticking adhesive surfaces, said carrier element being formed by a flexible tape including an acrylate foam;
wherein a first of the two self-sticking adhesive surfaces which faces the sealing element is formed at least partially of a silicone cement and a second of the two self-sticking adhesive surfaces includes an acrylate cement; and
wherein a primer is provided on said first of the adhesive surfaces that is formed at least partially of the silicone cement, said primer being provided between said first of the adhesive surfaces and the carrier element.
2. Seal arrangement as claimed in claim 1, wherein the silicone cement is a cross-linking silicone cement.
3. Seal arrangement as claimed in claim 1, wherein the adhesive surface which has the silicone cement has partial areas with another cement.
4. Seal arrangement as claimed in claim 1, wherein the second of said adhesive surfaces faces the application site.
5. Seal arrangement as claimed in claim 1, wherein the silicone cement is a cross-linking silicone cement and the other of the two self-sticking adhesive surfaces is formed of an adhesive optimally adapted for adherence to an attachment site to which the seal is applied.
6. Seal arrangement as claimed in claim 1, wherein the sealing element is an edge seal for a movable cover of an openable motor vehicle roof and the second of the two self-sticking adhesive surfaces being adapted for being affixed, in use, to a side edge of the movable cover.
7. Seal arrangement in accordance with claim 6, wherein the sealing element is an elongated extruded profile with a hollow chamber extending lengthwise within it.
8. An openable motor vehicle roof comprising:
a movable cover disposed in an opening in a fixed vehicle roof surface; and
a sealing arrangement for sealing said movable cover relative to said fixed vehicle roof surface,
wherein said sealing arrangement comprises:
a sealing element made of a silicone material;
a double-sided adhesive tape attached to the sealing element, said tape having a carrier element formed of an acrylate foam located between two self-sticking adhesive surfaces;
wherein a first of the two self-sticking adhesive surfaces which faces the sealing element is formed at least partially of a silicone cement and a second of the two self-sticking adhesive surfaces includes an acrylate cement; and
wherein a primer is provided on said first of the adhesive surfaces that is formed at least partially of the silicone cement, said primer being provided between said first of the adhesive surfaces and the carrier element.
9. Openable motor vehicle roof in accordance with claim 8, wherein the sealing element is an elongated extruded profile with a hollow chamber extending lengthwise within it.
10. A sealing element for use in motor vehicles, comprising
a sealing body made of silicone,
a carrier element formed of an acrylate foam,
first and second self-sticking adhesive surfaces, one on each side of the carrier element,
the first adhesive surface being bonded to the sealing body and being formed at least partially of a silicone cement, and
a protective film attached over the second self-sticking adhesive surface, said protective film being removable for attachment of the sealing body to an application site by said second self-sticking adhesive surface, and an intermediate adhesion layer between the first self-sticking adhesive surface and the carrier element, the intermediate adhesion layer being affixed to the carrier element to impart adhesion between the carrier element and the first adhesive surface which has been bonded, via the intermediate adhesion layer, to the carrier element with said silicone cement cross-linked.
11. Sealing element in accordance with claim 10, wherein the second adhesive surface is formed of an acrylate cement.
12. Sealing element in accordance with claim 10, wherein the second adhesive surface is formed directly by the acrylate foam of the carrier element.
13. Sealing element in accordance with claim 10, wherein the sealing body is an elongated extruded profile with a hollow chamber extending lengthwise within it.